David Karp

David Karp oversees a high-performance financial management and operations team that enables Gandeeva to execute its vision.

David was previously the CFO, and then CEO of CounterPath Corporation a Nasdaq listed public software company, where he drove improvement in revenue and led negotiation resulting in acquisition of CounterPath by Alianza at a premium of approximately 27% to market price. Prior to that, David was CFO of Chemokine Therapeutics Corp., where he led the company’s initial public offering and listing on the Toronto Stock Exchange (the “TSX”). Prior to that, David was Chief Financial Officer of Neuro Discovery Inc., an investment management company focused on biotechnology investing. As Vice President, Investment Banking for BMO Capital Markets (Nesbitt Burns), David raised capital and managed IPO’s and merger and acquisition assignments for life science companies.

David holds a Bachelor of Science degree in Mechanical Engineering from the University of Waterloo in Ontario and a Master’s in Business Administration from the Ivey School of Business at the University of Western Ontario in London, Ontario. He is a Chartered Financial Analyst (CFA).